title: Regulation of GABA and glutamate release from proopiomelanocortin neuron terminals in intact hypothalamic networks.
abstract: Hypothalamic proopiomelanocortin (POMC) neurons and their peptide products mediate important aspects of energy balance, analgesia, and reward. In addition to peptide products, there is evidence that POMC neurons can also express the amino acid transmitters GABA and glutamate, suggesting these neurons may acutely inhibit or activate downstream neurons. However, the release of amino acid transmitters from POMC neurons has not been thoroughly investigated in an intact system. In the present study, the light-activated cation channel channelrhodopsin-2 (ChR2) was used to selectively evoke transmitter release from POMC neurons. Whole-cell electrophysiologic recordings were made in brain slices taken from POMC-Cre transgenic mice that had been injected with a viral vector containing a floxed ChR2 sequence. Brief pulses of blue light depolarized POMC-ChR2 neurons and induced the release of GABA and glutamate onto unidentified neurons within the arcuate nucleus, as well as onto other POMC neurons. To determine whether the release of GABA and glutamate from POMC terminals can be readily modulated, opioid and GABA(B) receptor agonists were applied. Agonists for μ- and κ-, but not δ-opioid receptors inhibited transmitter release from POMC neurons, as did the GABA(B) receptor agonist baclofen. This regulation indicates that opioids and GABA released from POMC neurons may act at presynaptic receptors on POMC terminals in an autoregulatory manner to limit continued transmission. The results show that, in addition to the relatively slow and long-lasting actions of peptides, POMC neurons can rapidly affect the activity of downstream neurons via GABA and glutamate release.
authors.affiliation: Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Dicken
authors.forename: Ryan E
authors.initials: RE
authors.lastname: Tooker
authors.forename: Shane T
authors.initials: ST
authors.lastname: Hentges
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D000075402:Channelrhodopsins; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000235:genetics; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism*; D007031:Hypothalamus / Q000166:cytology*; D066298:In Vitro Techniques; D053444:Inhibitory Postsynaptic Potentials / Q000187:drug effects / Q000235:genetics; D008027:Light; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009415:Nerve Net / Q000502:physiology; D009474:Neurons / Q000166:cytology* / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D010455:Peptides / Q000494:pharmacology; D017729:Presynaptic Terminals / Q000378:metabolism*; D011333:Pro-Opiomelanocortin / Q000235:genetics / Q000378:metabolism*; D011810:Quinoxalines / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: D000701:Analgesics, Opioid; D000075402:Channelrhodopsins; D009292:Narcotic Antagonists; D018377:Neurotransmitter Agents; D010455:Peptides; D011810:Quinoxalines; C051844:norbinaltorphimine; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D009271:Naltrexone; C056723:FG 9041; D011333:Pro-Opiomelanocortin; C009862:connective tissue-activating peptide; D000324:Adrenocorticotropic Hormone